First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/BFECCACF.svg?ark=w1%2F20260526%2FBFECCACF)](https://nobleid.org/work/w1/20260526/BFECCACF)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors